These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7712466)

  • 21. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
    Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
    Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of 2-chloro-N10-substituted phenoxazines for reversing multidrug resistance in cancer cells.
    Thimmaiah KN; Jayashree BS; Germain GS; Houghton PJ; Horton JK
    Oncol Res; 1998; 10(1):29-41. PubMed ID: 9613455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of multidrug resistance gene expression in rat liver cells in response to acute treatment by the DNA-damaging agent methyl methanesulfonate.
    Fardel O; Payen L; Courtois A; Lecureur V; Guillouzo A
    Biochem Biophys Res Commun; 1998 Apr; 245(1):85-9. PubMed ID: 9535788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
    Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
    Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract.
    Limtrakul P; Khantamat O; Pintha K
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):525-30. PubMed ID: 15248030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents.
    Ihnat MA; Lariviere JP; Warren AJ; La Ronde N; Blaxall JR; Pierre KM; Turpie BW; Hamilton JW
    Clin Cancer Res; 1997 Aug; 3(8):1339-46. PubMed ID: 9815817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).
    Dumontet C; Duran GE; Steger KA; Beketic-Oreskovic L; Sikic BI
    Cancer Res; 1996 Mar; 56(5):1091-7. PubMed ID: 8640766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR.
    Tang XQ; Bi H; Feng JQ; Cao JG
    Acta Pharmacol Sin; 2005 Aug; 26(8):1009-16. PubMed ID: 16038636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
    Ogretmen B; McCauley MD; Safa AR
    Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Action of gossypol and rhodamine 123 on wild type and multidrug-resistant MCF-7 human breast cancer cells: 31P nuclear magnetic resonance and toxicity studies.
    Jaroszewski JW; Kaplan O; Cohen JS
    Cancer Res; 1990 Nov; 50(21):6936-43. PubMed ID: 2208159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-resistance to rhodamine 123 in Adriamycin- and daunorubicin-resistant Friend leukemia cell variants.
    Tapiero H; Munck JN; Fourcade A; Lampidis TJ
    Cancer Res; 1984 Dec; 44(12 Pt 1):5544-9. PubMed ID: 6498816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells.
    Figueroa-González G; Jacobo-Herrera N; Zentella-Dehesa A; Pereda-Miranda R
    J Nat Prod; 2012 Jan; 75(1):93-7. PubMed ID: 22148475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective toxicity of rhodamine 123 in carcinoma cells in vitro.
    Lampidis TJ; Bernal SD; Summerhayes IC; Chen LB
    Cancer Res; 1983 Feb; 43(2):716-20. PubMed ID: 6848187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Species-specific differences in the toxicity of rhodamine 123 towards cultured mammalian cells.
    Gupta RS; Dudani AK
    J Cell Physiol; 1987 Mar; 130(3):321-7. PubMed ID: 3558490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance.
    Coon JS; Knudson W; Clodfelter K; Lu B; Weinstein RS
    Cancer Res; 1991 Feb; 51(3):897-902. PubMed ID: 1988130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein.
    Siegsmund MJ; Kreukler C; Steidler A; Nebe T; Köhrmann KU; Alken P
    Urol Res; 1997; 25(1):35-41. PubMed ID: 9079744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of hTNF alpha potentiates cytotoxicity of taxol in human ovarian cancer lines.
    Berkova N; Pagé M
    Anticancer Res; 1995; 15(3):863-6. PubMed ID: 7645972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased rhodamine 123 uptake by carcinoma cells.
    Nadakavukaren KK; Nadakavukaren JJ; Chen LB
    Cancer Res; 1985 Dec; 45(12 Pt 1):6093-9. PubMed ID: 4063967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas.
    Mickisch GH; Kössig J; Keilhauer G; Schlick E; Tschada RK; Alken PM
    Cancer Res; 1990 Jun; 50(12):3670-4. PubMed ID: 2340516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.